Literature DB >> 22437076

Lymphotoxin-beta receptor activation on macrophages ameliorates acute DSS-induced intestinal inflammation in a TRIM30α-dependent manner.

Nadin Wimmer1, Barbara Huber, Anja K Wege, Nicola Barabas, Johann Röhrl, Klaus Pfeffer, Thomas Hehlgans.   

Abstract

Our previous studies indicated that LTβR activation mainly by T cell derived LTα₁β₂ is crucial for the control and down-regulation of intestinal inflammation. In order to dissect the cellular and molecular role of LTβR activation in the experimental model of DSS-induced intestinal inflammation, we have generated cell type-specific LTβR-deficient mice with specific ablation of LTβR expression on macrophages/neutrophils (LTβR((flox/flox))×LysM-Cre). These mice develop an exacerbated intestinal inflammation in our experimental model indicating that LTβR expression on macrophages/neutrophils is responsible for the control and down-regulation of the inflammatory reaction. These results were verified by adoptive transfer experiments of BMDM from wild-type and LTβR-deficient mice. Furthermore, transfer of activated CD4+ T cells derived from wild-type mice, but not from LTβR ligand-deficient mice attenuated the signs of intestinal inflammation. Finally, we demonstrate that LTβR activation on BMDM results in induction of TRIM30α, a negative regulator of NFκB activation. Concordantly, ablation of LTβR signaling results in the inability to induce TRIM30α expression concomitant with an increased expression of pro-inflammatory cytokines in our experimental model. Taken together, our data demonstrate that LTβR activation on macrophages by CD4+ T cell derived LTαβ controls the pro-inflammatory response by activation of a TRIM30α-dependent signaling pathway, crucial for the down-regulation of the inflammatory response in this experimental model.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22437076     DOI: 10.1016/j.molimm.2012.02.118

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  6 in total

1.  TRIM22 inhibits the TRAF6-stimulated NF-κB pathway by targeting TAB2 for degradation.

Authors:  Hui Qiu; Fang Huang; Han Xiao; Binlian Sun; Rongge Yang
Journal:  Virol Sin       Date:  2013-06-26       Impact factor: 4.327

2.  Lymphotoxin beta receptor signaling limits mucosal damage through driving IL-23 production by epithelial cells.

Authors:  E Macho-Fernandez; E P Koroleva; C M Spencer; M Tighe; E Torrado; A M Cooper; Y-X Fu; A V Tumanov
Journal:  Mucosal Immunol       Date:  2014-09-03       Impact factor: 7.313

Review 3.  Tripartite motif family proteins in inflammatory bowel disease: Mechanisms and potential for interventions.

Authors:  Rirong Chen; Yizhe Tie; Jinyu Lu; Li Li; Zhirong Zeng; Minhu Chen; Shenghong Zhang
Journal:  Cell Prolif       Date:  2022-04-04       Impact factor: 8.755

4.  An epithelial Nfkb2 pathway exacerbates intestinal inflammation by supplementing latent RelA dimers to the canonical NF-κB module.

Authors:  Meenakshi Chawla; Tapas Mukherjee; Alvina Deka; Budhaditya Chatterjee; Uday Aditya Sarkar; Amit K Singh; Saurabh Kedia; Josephine Lum; Manprit Kaur Dhillon; Balaji Banoth; Subhra K Biswas; Vineet Ahuja; Soumen Basak
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-22       Impact factor: 11.205

5.  Barbaloin Attenuates Mucosal Damage in Experimental Models of Rat Colitis by Regulating Inflammation and the AMPK Signaling Pathway.

Authors:  Ling Gai; Likai Chu; Rui Xia; Qian Chen; Xingwei Sun
Journal:  Med Sci Monit       Date:  2019-12-27

6.  Metabolic activation and colitis pathogenesis is prevented by lymphotoxin β receptor expression in neutrophils.

Authors:  Thomas Riffelmacher; Daniel A Giles; Sonja Zahner; Martina Dicker; Alexander Y Andreyev; Sara McArdle; Tamara Perez-Jeldres; Esmé van der Gracht; Mallory Paynich Murray; Nadine Hartmann; Alexei V Tumanov; Mitchell Kronenberg
Journal:  Mucosal Immunol       Date:  2021-02-10       Impact factor: 7.313

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.